

## **Global Small Molecule API Market Report and Forecast 2024-2032**

Market Report | 2023-09-15 | 160 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

### **Report description:**

Global Small Molecule API Market Report and Forecast 2024-2032

Global Small Molecule API Market Outlook

The Small Molecule API market was valued USD 195.6 billion in 2023, driven by increasing healthcare needs, a growing aging population, the prevalence of chronic diseases, and ongoing drug innovation has led to market growth across the globe. The market size is anticipated to grow at a CAGR of 6.8% during the forecast period of 2024-2032 to achieve a value of USD 352.7 billion by 2032.

Small Molecule API: Introduction

A Small Molecule API (Active Pharmaceutical Ingredient) refers to the chemical compound or molecule that is responsible for the therapeutic effect in a pharmaceutical drug. These small molecules are typically organic compounds with a relatively low molecular weight. They form the basis of many pharmaceutical drugs and are designed to interact with specific target molecules in the body to produce a desired therapeutic effect. Common examples of pharmaceutical drugs based on small molecule APIs include pain relievers like aspirin, antibiotics like penicillin, and cholesterol-lowering statins.

Small molecule APIs represent a significant portion of the pharmaceutical industry and have contributed to the development of numerous important drugs that treat a wide range of medical conditions. The discovery, development, and production of small molecule APIs involve a multidisciplinary approach, including chemistry, biology, pharmacology, and regulatory expertise

Key Trends in the Small Molecule API Market

- ☐ Increased Focus on Personalized Medicine: Advances in genomics and molecular biology have led to a growing emphasis on personalized medicine. Small molecule APIs can be tailored to specific genetic profiles or disease characteristics, allowing for more targeted and effective treatments. This trend is likely to continue as researchers gain a better understanding of the genetic basis of diseases.
- ☐ Rise of Biopharmaceuticals: While small molecule APIs remain important, the biopharmaceutical sector, which includes protein-based drugs and antibodies, has been growing rapidly. However, small molecules continue to play a crucial role in drug development, especially for diseases that can be effectively treated with small molecule interventions.
- ☐ Technological Advances in Drug Discovery: Advancements in computational biology, artificial intelligence, and high-throughput screening have revolutionized drug discovery. These technologies enable researchers to identify potential small molecule APIs

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

more efficiently and predict their interactions with target molecules, saving time and resources.

-□Focus on Rare Diseases: The orphan drug market, which includes drugs for rare diseases, has seen increased attention. Small molecule APIs that target specific rare diseases have gained traction due to regulatory incentives and the unmet medical needs of patients with these conditions.

#### Global Small Molecule Api Market Segmentation

The market can be categorised into type, therapeutic type, manufacturing method, applications, and region.

##### Market Breakup by type

- Synthetic/Chemical API
- Biological API

##### Market Breakup by Therapeutic Type

- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Dermatology
- Urology
- Others

##### Market Breakup by Manufacturing Method

- In-House
- Contract

##### Market Breakup by Applications

- Clinical
- Commercial

##### Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

#### Global Small Molecule Api Market Overview

Small molecule API (Active Pharmaceutical Ingredient) market has been a significant segment of the pharmaceutical industry. Small molecule APIs serve as the core components of many pharmaceutical drugs, driving the development of various therapeutic treatments. The small molecule API market has been experiencing steady growth due to factors such as increasing healthcare needs, a growing aging population, the prevalence of chronic diseases, and ongoing drug innovation. The market size is substantial, with a wide range of small molecule APIs being utilized in pharmaceutical products across various therapeutic areas. Small molecule APIs are manufactured on a global scale, with production facilities distributed across different regions. Certain

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

countries and regions, such as India and China, have been known for their significant contributions to API manufacturing due to cost-effectiveness and technical expertise.

The small molecule API market faces challenges related to increasing regulatory requirements, supply chain disruptions, and the need for continuous innovation. However, advancements in technology, personalized medicine, and increased focus on rare diseases present opportunities for growth and development.

#### Key Players in the Small Molecule API Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in small molecule api market are as follows:

- [ ] Albemarle Corporation
- [ ] Allergan
- [ ] Aurobindo Pharma
- [ ] Cambrex Corporation
- [ ] Dr. Reddy's Laboratories Ltd.
- [ ] GSK plc.
- [ ] Lonza
- [ ] Merck KGaA
- [ ] Novartis AG
- [ ] Pfizer Inc.
- [ ] Siegfried Holding AG
- [ ] Sun Pharmaceutical Industries Ltd.
- [ ] Teva Pharmaceutical Industries Ltd.
- [ ] Johnson Matthey
- [ ] Gilead Sciences, Inc.

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

#### Table of Contents:

- 1Preface
- 1.1Objectives of the Study
- 1.2Key Assumptions
- 1.3Report Coverage - Key Segmentation and Scope
- 1.4Research Methodology
- 2Executive Summary
- 3Global Small Molecule API Market Overview
- 3.1Global Small Molecule API Market Historical Value (2017-2023)
- 3.2Global Small Molecule API Market Forecast Value (2024-2032)
- 4Global Small Molecule API Market Landscape
- 4.1Global Small Molecule API Developers Landscape
- 4.1.1Analysis by Year of Establishment
- 4.1.2Analysis by Company Size
- 4.1.3Analysis by Region
- 4.2Global Small Molecule API Product Landscape
- 4.2.1Analysis by Type
- 4.2.2Analysis by Therapeutic Type

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.2.3Analysis by Applications
- 5Global Small Molecule API Market Dynamics
- 5.1Market Drivers and Constraints
- 5.2SWOT Analysis
- 5.3Porter's Five Forces Model
- 5.4Key Demand Indicators
- 5.5Key Price Indicators
- 5.6Industry Events, Initiatives, and Trends
- 5.7Value Chain Analysis
- 6Global Small Molecule API Market Segmentation
- 6.1Global Small Molecule API Market by Type
- 6.1.1Market Overview
- 6.1.2Synthetic/Chemical API
- 6.1.3Biological API
- 6.2Global Small Molecule API Market by Therapeutic Type
- 6.2.1Market Overview
- 6.2.2Autoimmune Diseases
- 6.2.3Oncology
- 6.2.4Metabolic Diseases
- 6.2.5Ophthalmology
- 6.2.6Cardiovascular Diseases
- 6.2.7Infectious Diseases
- 6.2.8Neurology
- 6.2.9Respiratory Disorders
- 6.2.10Dermatology
- 6.2.11Urology
- 6.2.12Others
- 6.3Global Small Molecule API Market by Manufacturing Method
- 6.3.1Market Overview
- 6.3.2In-House
- 6.3.3Contract
- 6.4Global Small Molecule API Market by Applications
- 6.4.1Market Overview
- 6.4.2Clinical
- 6.4.3Commercial
- 6.5Global Small Molecule API Market by Region
- 6.5.1Market Overview
- 6.5.2North America
- 6.5.3Europe
- 6.5.4Asia Pacific
- 6.5.5Latin America
- 6.5.6Middle East and Africa
- 7North America Small Molecule API Market
- 7.1Market Share by Country
- 7.2United States of America
- 7.3Canada
- 8Europe Small Molecule API Market

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.1Market Share by Country
- 8.2United Kingdom
- 8.3Germany
- 8.4France
- 8.5Italy
- 8.6Others
- 9Asia Pacific Small Molecule API Market
- 9.1Market Share by Country
- 9.2China
- 9.3Japan
- 9.4India
- 9.5ASEAN
- 9.6Australia
- 9.7Others
- 10Latin America Small Molecule API Market
- 10.1Market Share by Country
- 10.2Brazil
- 10.3Argentina
- 10.4Mexico
- 10.5Others
- 11Middle East and Africa Small Molecule API Market
- 11.1Market Share by Country
- 11.2Saudi Arabia
- 11.3United Arab Emirates
- 11.4Nigeria
- 11.5South Africa
- 11.6Others
- 12Patent Analysis
- 12.1Analysis by Type of Patent
- 12.2Analysis by Publication year
- 12.3Analysis by Issuing Authority
- 12.4Analysis by Patent Age
- 12.5Analysis by CPC Analysis
- 12.6Analysis by Patent Valuation
- 12.7Analysis by Key Players
- 13Grants Analysis
- 13.1Analysis by year
- 13.2Analysis by Amount Awarded
- 13.3Analysis by Issuing Authority
- 13.4Analysis by Grant Application
- 13.5Analysis by Funding Institute
- 13.6Analysis by NIH Departments
- 13.7Analysis by Recipient Organization
- 14Funding Analysis
- 14.1Analysis by Funding Instances
- 14.2Analysis by Type of Funding
- 14.3Analysis by Funding Amount

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 14.4Analysis by Leading Players
- 14.5Analysis by Leading Investors
- 14.6Analysis by Geography
- 15Partnership and Collaborations Analysis
- 15.1Analysis by Partnership Instances
- 15.2Analysis by Type of Partnership
- 15.3Analysis by Leading Players
- 15.4Analysis by Geography
- 16Regulatory Framework
- 16.1Regulatory Overview
- 16.1.1US FDA
- 16.1.2EU EMA
- 16.1.3INDIA CDSCO
- 16.1.4JAPAN PMDA
- 16.1.5Others
- 17Supplier Landscape
- 17.1Albemarle Corporation
- 17.1.1Financial Analysis
- 17.1.2Product Portfolio
- 17.1.3Demographic Reach and Achievements
- 17.1.4Mergers and Acquisition
- 17.1.5Certifications
- 17.2Allergan
- 17.2.1Financial Analysis
- 17.2.2Product Portfolio
- 17.2.3Demographic Reach and Achievements
- 17.2.4Mergers and Acquisition
- 17.2.5Certifications
- 17.3Aurobindo Pharma
- 17.3.1Financial Analysis
- 17.3.2Product Portfolio
- 17.3.3Demographic Reach and Achievements
- 17.3.4Mergers and Acquisition
- 17.3.5Certifications
- 17.4Cambrex Corporation
- 17.4.1Financial Analysis
- 17.4.2Product Portfolio
- 17.4.3Demographic Reach and Achievements
- 17.4.4Mergers and Acquisition
- 17.4.5Certifications
- 17.5Dr. Reddy's Laboratories Ltd.
- 17.5.1Financial Analysis
- 17.5.2Product Portfolio
- 17.5.3Demographic Reach and Achievements
- 17.5.4Mergers and Acquisition
- 17.5.5Certifications
- 17.6GSk plc.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.6.1Financial Analysis
- 17.6.2Product Portfolio
- 17.6.3Demographic Reach and Achievements
- 17.6.4Mergers and Acquisition
- 17.6.5Certifications
- 17.7Lonza
- 17.7.1Financial Analysis
- 17.7.2Product Portfolio
- 17.7.3Demographic Reach and Achievements
- 17.7.4Mergers and Acquisition
- 17.7.5Certifications
- 17.8Merck KGaA
- 17.8.1Financial Analysis
- 17.8.2Product Portfolio
- 17.8.3Demographic Reach and Achievements
- 17.8.4Mergers and Acquisition
- 17.8.5Certifications
- 17.9Novartis AG
- 17.9.1Financial Analysis
- 17.9.2Product Portfolio
- 17.9.3Demographic Reach and Achievements
- 17.9.4Mergers and Acquisition
- 17.9.5Certifications
- 17.10Pfizer Inc.
- 17.10.1Financial Analysis
- 17.10.2Product Portfolio
- 17.10.3Demographic Reach and Achievements
- 17.10.4Mergers and Acquisition
- 17.10.5Certifications
- 17.11Siegfried Holding AG
- 17.11.1Financial Analysis
- 17.11.2Product Portfolio
- 17.11.3Demographic Reach and Achievements
- 17.11.4Mergers and Acquisition
- 17.11.5Certifications
- 17.12Sun Pharmaceutical Industries Ltd.
- 17.12.1Financial Analysis
- 17.12.2Product Portfolio
- 17.12.3Demographic Reach and Achievements
- 17.12.4Mergers and Acquisition
- 17.12.5Certifications
- 17.13Teva Pharmaceutical Industries Ltd.
- 17.13.1Financial Analysis
- 17.13.2Product Portfolio
- 17.13.3Demographic Reach and Achievements
- 17.13.4Mergers and Acquisition
- 17.13.5Certifications

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.14Johnson Matthey
  - 17.14.1Financial Analysis
  - 17.14.2Product Portfolio
  - 17.14.3Demographic Reach and Achievements
  - 17.14.4Mergers and Acquisition
  - 17.14.5Certifications
- 17.15Gilead Sciences, Inc.
  - 17.15.1Financial Analysis
  - 17.15.2Product Portfolio
  - 17.15.3Demographic Reach and Achievements
  - 17.15.4Mergers and Acquisition
  - 17.15.5Certifications
- 18Global Small Molecule API Market - Distribution Model (Additional Insight)
  - 18.1Overview
  - 18.2Potential Distributors
  - 18.3Key Parameters for Distribution Partner Assessment
- 19Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20Company Competitiveness Analysis (Additional Insight)
  - 20.1Very Small Companies
  - 20.2Small Companies
  - 20.3Mid-Sized Companies
  - 20.4Large Companies
  - 20.5Very Large Companies
- 21Payment Methods (Additional Insight)
  - 21.1Government Funded
  - 21.2Private Insurance
  - 21.3Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

## Global Small Molecule API Market Report and Forecast 2024-2032

Market Report | 2023-09-15 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

| Select license | License             | Price     |
|----------------|---------------------|-----------|
|                | Single User License | \$2999.00 |
|                | Five User License   | \$3999.00 |
|                | Corporate License   | \$5999.00 |
|                |                     | VAT       |
|                |                     | Total     |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |   |
|---------------|----------------------|-------------------------------|---|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/>                    |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/>                    |
| Job title*    | <input type="text"/> |                               |   |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/>                    |
| Address*      | <input type="text"/> | City*                         | <input type="text"/>                    |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/>                    |
|               |                      | Date                          | <input type="text" value="2026-02-08"/> |
|               |                      | Signature                     | <input type="text"/>                    |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com